Role of Liraglutide Use in Patients With Heart Failure.
glp-1 analogs
glucagon-like peptide-1 receptor agonist (glp-1 ra)
heart failure with preserved ejection fraction
heart failure with reduced ejection fraction
liraglutide
literature review
management of heart failure
pub-med indexed research
review of clinical trials
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
06
12
2023
medline:
8
1
2024
pubmed:
8
1
2024
entrez:
8
1
2024
Statut:
epublish
Résumé
Heart failure is a clinical condition in which the heart is unable to maintain adequate cardiac output. Liraglutide is a glucagon-like peptide 1 (GLP-1) analogue that is used for the treatment of type 2 diabetes mellitus, but recent evidence suggests that it might have a beneficial role in treating heart failure. We conducted a review of existing literature and found five relevant studies. Data from these studies were extracted and then extrapolated into results following analysis. Four of the five studies found an increase in heart rate in heart failure patients. All five studies reported an increased rate of hospitalization. The five studies also showed an increased risk of adverse effects such as arrhythmia, ventricular tachycardia, atrial fibrillation, and worsening of heart failure. Given the scarcity of evidence in the available literature on liraglutide in heart failure, more research on this population is required.
Identifiants
pubmed: 38186489
doi: 10.7759/cureus.50065
pmc: PMC10769535
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e50065Informations de copyright
Copyright © 2023, Allam et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.